National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 23734 [2021-09268]
Download as PDF
<![CDATA[
23734
Federal Register / Vol. 86, No. 84 / Tuesday, May 4, 2021 / Notices
before the meeting about the actual time
allotted per speaker.
If possible, oral public commenters
should send a copy of their slides and/
or statement or talking points to NTPMeetings@icf.com by June 1, 2021.
Meeting Materials: The preliminary
meeting agenda is available on the
meeting web page (https://
ntp.niehs.nih.gov/go/165) and will be
updated one week before the meeting.
Individuals are encouraged to access the
meeting web page to stay abreast of the
most current information regarding the
meeting.
Background Information on the BSC:
The BSC is a technical advisory body
comprised of scientists from the public
and private sectors that provides
primary scientific oversight to the NTP.
Specifically, the BSC advises the NTP
on matters of scientific program content,
both present and future, and conducts
periodic review of the program for the
purpose of determining and advising on
the scientific merit of its activities and
their overall scientific quality. Its
members are selected from recognized
authorities knowledgeable in fields such
as toxicology, pharmacology, pathology,
epidemiology, risk assessment,
carcinogenesis, mutagenesis, cellular
biology, computational toxicology,
neurotoxicology, genetic toxicology,
reproductive toxicology or teratology,
and biostatistics. Members serve
overlapping terms of up to four years.
The BSC usually meets periodically.
The authority for the BSC is provided by
42 U.S.C. 217a, section 222 of the Public
Health Service Act (PHS), as amended.
The BSC is governed by the
provisions of the Federal Advisory
Committee Act, as amended (5 U.S.C.
app.), which sets forth standards for the
formation and use of advisory
committees.
Dated: April 15, 2021.
Brian R. Berridge,
Associate Director, National Toxicology
Program.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; PAR20–072, NIAID
Investigator Initiated Program Project
Applications (P01 Clinical Trial Not
Allowed).
Date: May 27, 2021.
Time: 10:00 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G45,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Vanitha Sundaresa Raman,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G45, Rockville, MD
20852, 301–761–7949, vanitha.raman@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: April 28, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–09268 Filed 5–3–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
BILLING CODE 4140–01–P
Prospective Grant of an Exclusive
Patent License: Natural Product Based
Nanoparticles as Dietary Management
and/or Treatment of Inflammatory
Related Diseases
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
National Institutes of Health
ACTION:
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
SUMMARY:
[FR Doc. 2021–09331 Filed 5–3–21; 8:45 am]
khammond on DSKJM1Z7X2PROD with NOTICES
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
VerDate Sep<11>2014
17:13 May 03, 2021
Jkt 253001
National Institutes of Health,
HHS.
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the Supplementary Information
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
section of this notice to MaDu, LLC
located at 2025 Broadway, Suite 23E,
New York, NY 10023.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before May 19, 2021 will be
considered.
Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Michelle A. Favila, Ph.D.,
Technology Transfer Manager, National
Institutes of Health, NCI Technology
Transfer Center by email
(michelle.favila@nih.gov).
SUPPLEMENTARY INFORMATION:
ADDRESSES:
Intellectual Property
HHS Ref No. E–154–2018–0: Binary
Lipid Bilayer-Containing Vesicles
Comprising Embedded Cytotoxic Agents
and Methods of Making and Using the
Same
1. United States Provisional Patent
Application No. No. 62/697,287 filed
July 12, 2018. [HHS Ref No. E–154–
2018–0–US–01]
2. International Patent Application
No. PCT/US2019/041464 filed July 11,
2019. [HHS Ref. No. E–154–2018–0–
PCT–02]
3. Canadian Patent Application No.
3106008 filed July 11, 2019. [HHS Ref
No. E–154–2018–0–CA–03]
4. European Patent Application
19746275.7 filed July 11, 2019. [HHS
Ref No. E–154–2018–0–EP–04]
5. Japanese Patent Application 2021–
500734 filed July 11, 2019. [HHS Ref
No. E–154–2018–0–JP–05] and
6. United States Patent Application
17/259,499 filed January 11, 2021 [HHS
Ref No. E–154–2018–0–US–01]
The patent and patent application
rights in these inventions have been
assigned and/or exclusively licensed to
the government of the United States of
America.
The prospective exclusive license
territory may be worldwide, and will be
less than the full patent term and the
field of use may be limited to the
following: Development and
commercialization of the Binary Lipid
Nanoparticle encapsulating known
natural products curcumin, vitamin D,
and/or L-serine that are Generally
Recognized as Safe for use as medical
foods, as defined by the FDA, or overthe-counter products for the
management of pain and inflammatoryrelated diseases. The prospective
licensee plans to develop Medical
Foods, which is defined by the FDA as
E:\FR\FM\04MYN1.SGM
04MYN1
]]>Agencies
[Federal Register Volume 86, Number 84 (Tuesday, May 4, 2021)]
[Notices]
[Page 23734]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-09268]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; PAR20-072, NIAID Investigator
Initiated Program Project Applications (P01 Clinical Trial Not
Allowed).
Date: May 27, 2021.
Time: 10:00 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G45,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Vanitha Sundaresa Raman, Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G45,
Rockville, MD 20852, 301-761-7949, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: April 28, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-09268 Filed 5-3-21; 8:45 am]
BILLING CODE 4140-01-P
